aber HALO!
Wedbush doesn't find any love in Halozyme Therapeutics (HALO +16.6%) ASCO presentation earlier today regarding clinical data from a Phase 1b trial of PEGPH20 that showed it helps to break down pancreatic cancers. The firm says that a positive tumor response outcome was expected. However, serial comparative PET imaging is a potentially more biologically relevant measure of disease activity, and it continues to expect a negative recommendation from the EMA on the approval of sub-cu Herceptin in Q2. 1 Comment
---------------------------------------------
Anbei: QU�BEC CITY, May 16, 2013 /PRNewswire via COMTEX/ -- Aeterna Zentaris Inc. AEZS +6.66% CA:AEZ +6.06% (the"Company") today announced that the Company's Senior Vice President and CFO, Dennis Turpin CPA CA, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, May 22, 2013, at 10:30 am (Eastern), in room A/B of the Toronto Board of Trade, in Toronto, Canada.
Nur gepostet, damit der Aktiendepotvergleich mit 56 Teilnehmern wieder kurzzeitig oben landet!
PP
|